FDA Grants Priority Review for Nuvalent's Neladalkib NDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2026
0mins
Source: Newsfilter
- NDA Acceptance: Nuvalent's New Drug Application for neladalkib has been accepted by the FDA for filing with Priority Review, targeting a PDUFA action date of November 27, 2026, which is expected to accelerate its market entry in the ALK-positive NSCLC space and significantly enhance the company's market share in this area.
- Clinical Trial Data Support: The application is based on data from the global registrational ALKOVE-1 clinical trial involving ALK-positive NSCLC patients, demonstrating neladalkib's efficacy in TKI-pretreated patients, thereby strengthening its competitive position in the market.
- International Expansion Strategy: Dr. Georg Pirmin Meyer joins Nuvalent as Chief International Officer to spearhead global expansion strategies, leveraging his extensive experience in international markets to establish a strong foundation for growth outside the U.S.
- Significant Product Potential: As an ALK-selective inhibitor, neladalkib is designed to overcome limitations of existing ALK inhibitors with promising CNS penetrance, expected to provide better treatment options for patients with brain metastases, thereby improving patient outcomes and quality of life.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVL
Wall Street analysts forecast NUVL stock price to rise
16 Analyst Rating
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 123.250
Low
125.00
Averages
140.86
High
158.00
Current: 123.250
Low
125.00
Averages
140.86
High
158.00
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GSK in Talks to Acquire Cancer Drugmaker Nuvalent for Over $9 Billion
- Acquisition Talks: UK pharmaceutical group GSK is in discussions to acquire cancer drugmaker Nuvalent for over $9 billion, a move that would significantly enhance GSK's market position in cancer treatment.
- Positive Market Reaction: According to the Financial Times, the market has reacted positively to GSK's acquisition intentions, with investors expressing optimism about its future growth potential, which may drive GSK's stock price higher.
- Industry Consolidation Trend: This acquisition negotiation reflects a consolidation trend within the pharmaceutical industry, particularly in cancer treatment, as GSK could gain access to Nuvalent's innovative drug pipeline, thereby enhancing its R&D capabilities.
- Strategic Implications: If the deal goes through, GSK will be able to expand its product portfolio, further solidifying its competitive edge in the global pharmaceutical market, and potentially accelerating the time-to-market for new drugs to meet the growing market demand.
See More
Ademi LLP Investigates Nuvalent's Transaction Compliance
- Shareholder Rights Investigation: Ademi LLP is investigating Nuvalent's transaction with GSK plc for potential breaches of fiduciary duty and other legal violations, with a total transaction value of approximately $10.6 billion, indicating a threat to shareholder rights as stockholders will receive $124 per share.
- Competing Transaction Limitations: The transaction agreement imposes significant penalties on Nuvalent for accepting competing bids, which could undermine shareholder interests and affect the company's future market competitiveness by limiting strategic options.
- Board Responsibility Review: The investigation will focus on whether Nuvalent's board has fulfilled its fiduciary duties to all shareholders, ensuring that there are no preferential treatments for insiders during the transaction process, thereby maintaining transparency and fairness in corporate governance.
- Litigation Expertise: Ademi LLP specializes in shareholder litigation involving buyouts, mergers, and individual shareholder rights, indicating its expertise in handling similar cases and potentially providing legal support and remedies for affected shareholders.
See More
UK Tech Ecosystem Rebounds with New Growth
- Ecosystem Ranking: According to the Global Tech Ecosystem Index by Dealroom, London is ranked as the world's fourth-largest tech ecosystem, reclaiming the top spot in Europe, demonstrating strong performance in venture capital and unicorn creation, with London tech companies raising $17.7 billion last year.
- Startup Gathering: London Tech Week attracted over 30,000 attendees, including 8,250 startups and 1,500 investors, showcasing the region's vibrancy in tech innovation and investment despite challenges following Brexit.
- Emerging Tech Cluster: The King's Cross area is becoming a new tech hub, with OpenAI and Anthropic set to open offices, joining companies like Google DeepMind and Meta, highlighting the area's advantages in talent density and innovation capacity.
- Policy and Market Risks: Despite the UK's strengths in AI and fintech, analysts warn that the market underestimates the impact of political risks, particularly in light of the Makerfield by-election and other political events, which could pose potential impacts on the market.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Nuvalent, Inc. (NASDAQ: NUVL) regarding its sale to GSK plc for $124.00 per share in cash, potentially infringing on shareholder rights.
- Merger Transaction Review: SUNation Energy, Inc. (NASDAQ: SUNE) is merging with Suniva, which is expected to result in SUNation shareholders owning approximately 1.8% of the combined entity, prompting Halper Sadeh LLC to seek increased compensation for shareholders.
- Shareholder Rights Protection: Organon & Co. (NYSE: OGN) is selling to Sun Pharmaceutical Industries Limited for $14.00 per share, with Halper Sadeh LLC encouraging Organon shareholders to understand their legal rights.
- Cash Acquisition Focus: Taylor Morrison Home Corporation (NYSE: TMHC) is being sold to Berkshire Hathaway Inc. for $72.50 per share in cash, and Halper Sadeh LLC will represent shareholders in seeking additional disclosures and compensation.
See More
US Stocks Close: Nasdaq Hits 5-Week Low Amid Market Rotations
- Market Volatility: The S&P 500 index fell by 0.26% and the Nasdaq 100 dropped by 1.12% on Tuesday, indicating a shift to a downward trend after an early advance, reflecting investor concerns over tech stocks.
- Energy Price Impact: WTI crude oil prices plunged by 3% to a seven-week low, leading to widespread declines in energy producers' stocks, which exacerbated the overall market weakness and highlighted the direct impact of oil price fluctuations on related sectors.
- Real Estate Market Recovery: US existing home sales rose to 4.17 million in April, a five-month high, boosting the stocks of builders and suppliers, indicating that a recovery in the real estate market could provide positive signals for the economy.
- International Trade Data Improvement: China's May exports increased by 19.4% year-on-year, surpassing expectations, showcasing potential for global economic growth, which may positively influence the US market, despite ongoing uncertainties.
See More
Tech Stocks Retreat as DraftKings Soars on SEC Filing
- Semiconductor Stocks Decline: The VanEck Semiconductor ETF fell 5% as the tech sell-off intensified, with AMD and Nvidia dropping 8% and nearly 3% respectively, indicating a waning market confidence in the semiconductor sector that could impact future investment decisions.
- DraftKings Strong Growth: DraftKings' Predictions offering saw a 24% month-over-month increase to $1.3 billion in May, with annualized total volume traded rising 34% to $3.1 billion, showcasing robust performance in the sports betting market that may attract more investor interest.
- Apple Stock Retreats: Despite unveiling new AI software at its Worldwide Developers Conference, Apple's stock dropped over 3%, reflecting market reactions that fell short of expectations, potentially affecting the company's short-term market performance.
- Nuvalent Acquisition Agreement: GSK announced a $10.6 billion agreement to acquire Nuvalent, leading to a 39% surge in Nuvalent's shares, which not only boosts its market value but may also enhance GSK's competitive position in the biopharmaceutical sector.
See More
GSK in Talks to Acquire Cancer Drugmaker Nuvalent for Over $9 Billion
- Acquisition Talks: UK pharmaceutical group GSK is in discussions to acquire cancer drugmaker Nuvalent for over $9 billion, a move that would significantly enhance GSK's market position in cancer treatment.
- Positive Market Reaction: According to the Financial Times, the market has reacted positively to GSK's acquisition intentions, with investors expressing optimism about its future growth potential, which may drive GSK's stock price higher.
- Industry Consolidation Trend: This acquisition negotiation reflects a consolidation trend within the pharmaceutical industry, particularly in cancer treatment, as GSK could gain access to Nuvalent's innovative drug pipeline, thereby enhancing its R&D capabilities.
- Strategic Implications: If the deal goes through, GSK will be able to expand its product portfolio, further solidifying its competitive edge in the global pharmaceutical market, and potentially accelerating the time-to-market for new drugs to meet the growing market demand.
See More
Ademi LLP Investigates Nuvalent's Transaction Compliance
- Shareholder Rights Investigation: Ademi LLP is investigating Nuvalent's transaction with GSK plc for potential breaches of fiduciary duty and other legal violations, with a total transaction value of approximately $10.6 billion, indicating a threat to shareholder rights as stockholders will receive $124 per share.
- Competing Transaction Limitations: The transaction agreement imposes significant penalties on Nuvalent for accepting competing bids, which could undermine shareholder interests and affect the company's future market competitiveness by limiting strategic options.
- Board Responsibility Review: The investigation will focus on whether Nuvalent's board has fulfilled its fiduciary duties to all shareholders, ensuring that there are no preferential treatments for insiders during the transaction process, thereby maintaining transparency and fairness in corporate governance.
- Litigation Expertise: Ademi LLP specializes in shareholder litigation involving buyouts, mergers, and individual shareholder rights, indicating its expertise in handling similar cases and potentially providing legal support and remedies for affected shareholders.
See More
UK Tech Ecosystem Rebounds with New Growth
- Ecosystem Ranking: According to the Global Tech Ecosystem Index by Dealroom, London is ranked as the world's fourth-largest tech ecosystem, reclaiming the top spot in Europe, demonstrating strong performance in venture capital and unicorn creation, with London tech companies raising $17.7 billion last year.
- Startup Gathering: London Tech Week attracted over 30,000 attendees, including 8,250 startups and 1,500 investors, showcasing the region's vibrancy in tech innovation and investment despite challenges following Brexit.
- Emerging Tech Cluster: The King's Cross area is becoming a new tech hub, with OpenAI and Anthropic set to open offices, joining companies like Google DeepMind and Meta, highlighting the area's advantages in talent density and innovation capacity.
- Policy and Market Risks: Despite the UK's strengths in AI and fintech, analysts warn that the market underestimates the impact of political risks, particularly in light of the Makerfield by-election and other political events, which could pose potential impacts on the market.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Nuvalent, Inc. (NASDAQ: NUVL) regarding its sale to GSK plc for $124.00 per share in cash, potentially infringing on shareholder rights.
- Merger Transaction Review: SUNation Energy, Inc. (NASDAQ: SUNE) is merging with Suniva, which is expected to result in SUNation shareholders owning approximately 1.8% of the combined entity, prompting Halper Sadeh LLC to seek increased compensation for shareholders.
- Shareholder Rights Protection: Organon & Co. (NYSE: OGN) is selling to Sun Pharmaceutical Industries Limited for $14.00 per share, with Halper Sadeh LLC encouraging Organon shareholders to understand their legal rights.
- Cash Acquisition Focus: Taylor Morrison Home Corporation (NYSE: TMHC) is being sold to Berkshire Hathaway Inc. for $72.50 per share in cash, and Halper Sadeh LLC will represent shareholders in seeking additional disclosures and compensation.
See More
US Stocks Close: Nasdaq Hits 5-Week Low Amid Market Rotations
- Market Volatility: The S&P 500 index fell by 0.26% and the Nasdaq 100 dropped by 1.12% on Tuesday, indicating a shift to a downward trend after an early advance, reflecting investor concerns over tech stocks.
- Energy Price Impact: WTI crude oil prices plunged by 3% to a seven-week low, leading to widespread declines in energy producers' stocks, which exacerbated the overall market weakness and highlighted the direct impact of oil price fluctuations on related sectors.
- Real Estate Market Recovery: US existing home sales rose to 4.17 million in April, a five-month high, boosting the stocks of builders and suppliers, indicating that a recovery in the real estate market could provide positive signals for the economy.
- International Trade Data Improvement: China's May exports increased by 19.4% year-on-year, surpassing expectations, showcasing potential for global economic growth, which may positively influence the US market, despite ongoing uncertainties.
See More
Tech Stocks Retreat as DraftKings Soars on SEC Filing
- Semiconductor Stocks Decline: The VanEck Semiconductor ETF fell 5% as the tech sell-off intensified, with AMD and Nvidia dropping 8% and nearly 3% respectively, indicating a waning market confidence in the semiconductor sector that could impact future investment decisions.
- DraftKings Strong Growth: DraftKings' Predictions offering saw a 24% month-over-month increase to $1.3 billion in May, with annualized total volume traded rising 34% to $3.1 billion, showcasing robust performance in the sports betting market that may attract more investor interest.
- Apple Stock Retreats: Despite unveiling new AI software at its Worldwide Developers Conference, Apple's stock dropped over 3%, reflecting market reactions that fell short of expectations, potentially affecting the company's short-term market performance.
- Nuvalent Acquisition Agreement: GSK announced a $10.6 billion agreement to acquire Nuvalent, leading to a 39% surge in Nuvalent's shares, which not only boosts its market value but may also enhance GSK's competitive position in the biopharmaceutical sector.
See More
